KPTI

Karyopharm Therapeutics Inc

• TipRanks·2d ago

  Karyopharm (KPTI) Earnings Call: Promise vs. Pressure

• Seeking Alpha·08/18 13:58

  Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis

• TipRanks·08/18 12:45

  Largest borrow rate increases among liquid names

• TipRanks·08/18 02:10

  Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Karyopharm Therapeutics (KPTI)

• Simply Wall St·08/16 12:51

  Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40

• NASDAQ·08/14 05:24

  Karyopharm Q2 Net Loss Expands; Reaffirms 2026 Revenue Guidance; Plans SNDA For Selinexor In August

• Benzinga·08/13 12:54

  Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

• NASDAQ·08/13 12:50

  Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

• Seeking Alpha·08/13 11:57

  Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook

• Benzinga·08/13 11:32

  Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est

• Dow Jones·08/13 11:32

  *Karyopharm Therapeutics Backs 2026 Rev $130M-$150M >KPTI

• Dow Jones·08/13 11:30

  Press Release: Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

• Dow Jones·08/13 11:30

  *Karyopharm Therapeutics 2Q Rev $33.4M >KPTI

• Seeking Alpha·08/12 16:21

  Karyopharm Therapeutics Q2 2026 Earnings Preview

• NASDAQ·08/11 21:25

  Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates